Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Viatris Inc (VTRS) vs 22nd Century Group Inc (XXII) Price & Performance

Viatris IncTrade
22nd Century Group IncTrade

Price performance (Past 24H)

Key statistics

Viatris Inc vs 22nd Century Group Inc — how do they compare? Viatris Inc trades at $17.58 (market cap $19.79B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: Viatris Inc is far larger — about 13281.9× 22nd Century Group Inc's market cap, and Viatris Inc pays a 2.83% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.

VTRSXXII
Market Cap
$19.79B$1.49M
Sector
HealthTechnology
52-Week High
$17.39$1.07K
52-Week Low
$8.74$3.90
Enterprise Value
$32.00B-$6.74M
Dividend Yield
2.83%

Returns comparison

Trailing returns across standard periods

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS

About 22nd Century Group Inc

22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.

Read more on XXII